Brian O Mahony/X
Apr 26, 2026, 11:55
Brian O Mahony: Pierce Highlights Unique Inhibitor Cases in AAV-ET3 FVIII Gene Therapy Trial
Brian O Mahony, CEO of Irish Haemophilia Society, Former President of WFH and EHC, shared a post on X:
”Pierce on Gene Therapy safety WFH Congress 2026 AAV-ET3 FVIII Human Porcine hybrid Gene Therapy trial in US.
Both participamts developed inhibitors.
These are the only inhibitors seen to date in all the haemophilia clinical trials.”
Stay updated with Hemostasis Today.
-
Apr 26, 2026, 12:01David McIntosh: Raising Awareness on the Worldwide Shortage of Plasma-Derived Medicines
-
Apr 26, 2026, 12:00José Antonio García Erce: Where Is the Limit in Blood Donation Age?
-
Apr 26, 2026, 11:59Tomas Holubec: A New Chapter in Cardiac Surgery in Nuremberg
-
Apr 26, 2026, 11:58Emna Hammami: Great First Session at the EHA SWG Scientific Meeting on Bleeding and Platelet Disorders
-
Apr 26, 2026, 11:56Sami Moellmer-Gomez: Glad to Present My Recent Work at the UNC 12th Symposium on Hemostasis
-
Apr 26, 2026, 11:51Mavis Agnes Kisakye: A Patient Story That Shows the Power of Humanitarian Aid
-
Apr 26, 2026, 11:38Ney Carter Borges: Perioperative Cardiovascular Medication Management in Noncardiac Surgery
-
Apr 26, 2026, 11:25Giacomo Centenaro: I Arrived to Represent My Country and Community at WFH 2026
-
Apr 26, 2026, 11:14Ali H. Hajeer: A New Tool to Align HLA Alleles with Serologic Classifications